IndicationProtocolNCT number

Utah Cancer Specialists

Last Updated June 1, 2021
Protoccol Number
BRE009 Breast A Phase III Randomised Study Assessing the Efficacy andSafety of Study Drug+ Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Locally Advanced (Inoperable) or Metastatic ER PR negative HER2+ Triple Negative Breast Cancer NCT03997123
BRE010 Breast A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Study Drug Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer NCT03961698
BRE011 Breast A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Study Drug plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy NCT04752332
COL001 Colorectal A study of a Study Drug as Monotherapy or in Combination with other Anticancer Therapies for the
Treatment of Urothelial Cancer		 NCT04479436
GAL001 Gallbladder A Phase 3, Open-Label, Randomized Study of Study Drug Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of
Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements		 NCT04093362
GAS004 Gastric A Phase 2 Randomized, Multicenter,  Study Drug and Chemotherapy Versus Placebo with Study Drug and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous,Non-Small Cell Lung Cancer (NSCLC) NCT04265534
GAS003 Gastric A Phase 3 Double-Blind, Randomized Study Drug Plus CAPOX Compared with Placebo Plus CAPOX as 1 Line Treatment of Subjects with Claudin18.2+, HER2-Phase 2/3 Trial to Evaluate Study Drug in Combination With Study Drug and Chemotherapy or Study Drug and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT04082364
GAS002 Gastric A Phase 3 Double-Blind, Randomized Study Drug Plus CAPOX Compared with Placebo Plus CAPOX as 1 L Treatment of Subjects with Claudin18.2+, HER2-Negative,Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction NCT03653507
MYE001 Myelofibrosis A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of a Study Drug Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis NCT03222609
HEA001 Head and Neck A phase 3 Study of a Study Drug in Combination with Paclitaxel, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT04338399
HEA002 Head and Neck Phase 3 study of Study Drug in combination with platinum-based chemotherapy and standard fractionation intensitymodulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck NCT04459715
LYM004 Lymphona  A Study ofStudy Drug Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed-Refractory, Follicular Lymphoma Grade 1 to 3a or RR Marginal Zone Lymphoma NCT04680052
LUN006 Lung NSCLC Phase 3 Randomized Study of Study DrugVersus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations  NCT0465652
LUN005 Lung NSCLC A Randomized, Open-label Phase 3 Study of Combination of Study Drug Therapies Compared with Carboplatin-Pemetrexed, in Patients with  EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT04538664
LUN004 Lung SCLC  A Phase 3, Open-label,Randomized Study of a Drug Administered Sequentially with a Platinum Doublet or a Platinum Doublet Plus Study Drug in Third-
Line or Beyond Small Cell Lung Cancer		 NCT03699956
MEL001 Melanoma A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Study Drug and Nivolumab Versus Nivolumab Alone, After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) NCT04410445
MDS001 MDS High Risk A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Study Drug in Combination with Study Drug in Patients Newly Diagnosed with Higher-Risk MyelodysplasticSyndrome (Higher-Risk MDS) NCT04401748
MDS001 MDS Low Risk A Phase3,Open-Label,Randomized Study to Compare the Efficiancy and Safety of Luspatercept versus Epoetin ALFA for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk MDS in ESA Naïve Subjects who Require Red Blood Cell Transfusions NCT03682536
PAN001 Pancreas A phase III study of irinotecan liposome injection, oxaliplatin, 5-FU/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas NCT04083235
PRO003 Prostate A Phase 3 Randomized, Placebo-controlled, Double-blind Study of a Drug in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Predisone for Treatment of Subjects with Metastatic Prostate Cancer NCT03748641
STA002 Advanced Solid Tumor A Phase 1 Study for Study Particiants with BRAFF V-600 Mutation In Melanoma  or Other Solid Tumors NCT03864042
STA005 Advanced Solid Tumor A Phase 2 Study of a Drug in Combination Therapies in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm)
and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer		 NCT04123366
STA006 Solid Tumor A Phase 1/2 Study of  a New Investigatinal Combination drug in Subjects With Advanced Solid Tumors NCT03861793
STA007 Solid Tumor A Phase 2 Study of a Drug in Combination Therapies in Participants with Neuregulin-1 (NGR1) Fusion Positive Locally Advanced or Metastatic Solid Tumors NCT04383210
URO001 Urothelial A Phase 1 Study of a Study Drug  in Combination with other Anticancer Therapies for the Treatment of Urothelial Cancer NCT03288545
NonThera001 Solid Tumor Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors N/A
Non Thera002 Liquid Tumor  An Observational Study to Collect and Assess Tissue Samples From Subjects with Documented Hematologic Malignancy N/A